CLC-2 is a voltage-gated chloride channel expressed ubiquitously in mammalian tissue. Studies to define how CLC-2 contributes to normal and pathophysiological brain function have produced controversial results, in part due to the absence of precise pharmacological tools for modulating CLC-2 function. Herein, we describe the development and optimization of a new small-molecule inhibitor of CLC-2, AK-42, that exhibits unprecedented potency and specificity. Computational docking, validated by mutagenesis and kinetic studies, indicates that AK-42 binds to an extracellular vestibule above the channel pore. AK-42 acutely and specifically inhibits CLC-2 currents in CA1 hippocampal pyramidal neurons. Use of AK-42 in an established thalamic-slice model for studying epilepsy suggests a role for CLC-2 in modulating electrical excitability and implicates CLC-2 as a possible anti-epileptic target. These results establish AK-42 as a powerful new tool for investigating CLC-2 physiology in the central nervous system.
Introduction
Although Clis the most abundant anion in the brain, its role in neuronal signaling has been subject to less scrutiny relative to cations, such as Na + , K + , and Ca 2+ . The inattention to Clmay be traced back to the pioneering work on neuronal action potentials by Hodgkin and Huxley, who characterized Clas responsible for only minor "leak" currents 1 . While it is now recognized that Clmovement is critical for homeostatic functions in the brain, including regulation of cell volume and pH [2] [3] [4] [5] [6] , the role of Clin excitability remains incompletely understood.
The best-studied effects of Clon excitability are at GABAergic synapses, the major inhibitory synapses in the mammalian brain 7, 8 . A voltage-gated chloride channel, CLC-2, is also widely expressed in the central nervous system (CNS), but its function remains poorly defined. modification of the diarylamine core. Examination of other non-steroidal anti-inflammatory drugs (NSAID) within our initial screen (Extended Data Table 1) revealed that the interaction of MCFA with CLC-2 does not simply derive from non-specific Coulombic attraction of the anionic carboxylate group to the electropositive ion conduction pore. Most notably, mefenamic acid and diclofenac, which are structurally analogous to MCFA, have negligible inhibitory activity at 30 µM. A small collection of angiotensin (AT1) receptor antagonists called sartans that are anionic at physiological pH due to the presence of a tetrazole, carboxylic acid, or both also failed to inhibit Clcurrents to any appreciable extent at 30 µM. Other reported small-molecule modulators of CLC channels (BIM1, BIM4, DPC, NFA, and lubiprostone) 34, 36, 37, 41, 42 displayed no efficacy against CLC-2 (Extended Data Table 1 ).
Structure-Activity Relationship (SAR) studies
To enable SAR studies of MCFA, we developed a general synthesis of substituted diarylamines (Figure 1A) .
Using this strategy, we prepared a total of 51 MCFA derivatives. The results from evaluation of the first 37 derivatives tested ( Figure 1B) guided the design of an additional 14 compounds (Extended Data Figure 2 ).
An initial systematic examination was performed to assess the effects of -Cl and -Me substituents on the western aryl ring of the MCFA scaffold (Figure 1 , green, orange, and red boxes). Removal of either the C2-or C6-Cl group (AK-3, AK-6) resulted in a ~50% decrease in potency relative to MCFA. By contrast, the potency of AK-4, which lacks the C3-Me group, was unchanged. Other di-and tri-chlorinated analogs, including AK-1, AK-2, AK-5, and AK-7, were ineffective at blocking CLC-2 (IC50 ≥ 120 µM). C2,C6-Substitution with Cl-or Me-groups (AK-4 and AK-15, respectively) proved imperative; introduction of sterically smaller (-F, AK-8) or larger (-Et, AK-21) substituents significantly reduced inhibitor potency. These results suggest that a twisted geometry of the diarylamine scaffold is necessary for inhibition.
The mildly enhanced potency of MCFA over AK-4 (IC50 = 14 µM vs. 22 µM) led us to query the effect of replacing the C3-Me group in MCFA with alternative substituents (Figure 1, blue box) . Initially, a series of four compounds was prepared in which a -OMe, isopropenyl, -Et, or -CF3 group was introduced at C3 (AK-13, AK-14, AK-16, and AK-17, respectively). With the exception of AK-17, these ligands were nearly 2-fold more potent than MCFA. In a second round of SAR, incorporation of sterically larger groups at C3, which included -OBn, -Ph, and -OCH2 c Hx (AK-24, AK-25, and AK-26, respectively), resulted in an additional enhancement in potency.
Among these derivatives, AK-24 was identified as the most effective inhibitor of CLC-2 with an IC50 of 0.6 µM.
We next evaluated the influence of the MCFA carboxylate group on ligand binding (Figure 1, purple) . This study included moving the position of the carboxylate from C1' to C5' and C6' on the eastern ring (AK-20, AK- 19) and replacing the carboxylate with other charged substituents, including -OSO3 -, -PO3 2-, -PO2(OEt) -, -tetrazolate, and -CH2CO2 -(AK-9, AK-34, AK-35, AK-18, and diclofenac, respectively). A neutral analog of MCFA, AK-36, in which the carboxylate group was converted to a primary carboxamide, was also prepared. All eight of these compounds displayed reduced potency relative to MCFA. From these data, the efficacy of carboxamide AK-36 is perhaps most surprising, as this derivative is only ~3-fold less potent than MCFA despite lacking the anionic charge. This result indicates that ligand-protein binding is not purely dictated by charge-charge interactions.
Additional ligand SAR effects were revealed by varying substituent groups on the eastern ring of MCFA with the western ring held fixed (Figure 1 , magenta and cyan). A methyl scan at positions C4', C5', and C6' (AK-10, AK-11, and AK-12, respectively) showed diminished potency for all three isomers, with the most significant loss resulting from C6' substitution. Collectively, these findings intimate that the eastern ring of MCFA is sequestered in a restricted binding pocket. Given these data, we prepared four isomeric nicotinic acid derivatives (AK-30, AK-31, AK-32, and AK-33), reasoning that introduction of a N-atom in this region of the inhibitor would alter steric size and potentially enable stabilizing hydrogen bonding interactions with the protein. While three of these compounds display substantially reduced potency, the potency of one derivative, AK-33, is improved 7-fold over MCFA (IC50 = 2 µM). Given that these isomers should have similar cLogP values and polar surface areas, this finding suggests that the N-atom at the 3' position engages in a specific interaction between AK-33 and CLC-2.
In light of our results with AK-24 and AK-33, we synthesized AK-42, a derivative that combines the C3-OBn substituent on the western ring with the C3'-nicotinic acid on the eastern half (Figure 2A) . AK-42 is almost three orders of magnitude more potent than MCFA (Figure 2B) . Manual patch-clamp experiments on CHO cells transiently transfected with rat CLC-2 indicate comparable AK-42 potency to that determined for human CLC-2 using the IWB (Extended Data Figure 3 , IC50 value of 14 nM for rat CLC-2). To our knowledge, AK-42 is the most potent small-molecule inhibitor against any CLC homolog.
AK-42 selectivity, specificity, and binding site
To assess the utility of AK-42 as a tool compound for studies of CLC-2 physiology, we evaluated the selectivity of this ligand for CLC-2 over other protein targets. Electrophysiological recordings of CLC-1, the most closely related homolog to CLC-2 (55% sequence identity), revealed >4 orders of magnitude reduced sensitivity to AK-42 ( Figure 2C) . By comparison, the original 'hit' compound, MCFA exhibits only modest selectivity (<10-fold) between the two homologs (Extended Data Table 3 ).
AK-42 was next tested against a broad panel of channels, receptors, and transporters, using a comprehensive screen developed and conducted by the National Institutes of Health Psychoactive Drug Screening Program (NIH PDSP) to evaluate the specificity of small-molecules against CNS targets 43 . Depending on the identity of the receptor, primary binding assays or functional assays were performed with each compound at 10 µM, a concentration well above the IC50 of AK-42 for CLC-2 and at least 4 times higher than the inhibitor concentrations used in our primary cell experiments (vide infra). In these assays, no notable off-target protein-binding effects were observed; for the 8 targets exhibiting a response of >50% at 10 µM (Supplemental Table 2 ), secondary assays confirmed that the effects were weak or negligible (Supplemental Figure 2) .
To gain insight into the molecular basis for the CLC homolog selectivity, we performed a computational docking study and experimentally tested the binding-site predictions. Absent a high-resolution structure of CLC-2, we took advantage of a CLC-2 structural homology model we had developed and refined with 600 µs of molecular dynamics simulations 44 . Based on the kinetics and reversibility of inhibition (Extended Data Figures   3, 4) , we reasoned that AK-42 is likely binding to the extracellular side of channel pore. Docking of AK-42 to the extracellular side of the CLC-2 model preferentially places this ligand near the outer vestibule of the ionpermeation pathway, in a similar site to that targeted by anionic inhibitors in CLC-Ka 35, 36 . Notably, we found that AK-42 does not dock to the cryo-EM structure of CLC-1 (6COY) 45 , in line with our functional studies on selectivity ( Figure 2C) . While the top docking poses in our CLC-2 model vary in the specific interactions predicted, all place AK-42 in the same general binding site. A representative docking pose to the predicted CLC-2 binding site, along with a schematic of the 14 residues observed near AK-42 in all models, is shown in Figure   3A , B.
To test the binding-site predictions of this model, we first examined mutations at the two charged residues located within this proposed pocket, K210 and K400, reasoning that at least one of these could contribute to electrostatic stabilization of the anionic inhibitor molecule. Mutations at K210, a highly conserved residue, resulted in significantly diminished sensitivity to AK-42 (Figure 3C, D) . Notably, the effectiveness of AK-42 is reduced even against the charge-conserved mutant, K210R. Accordingly, the K210 residue may play a critical role in fixing the inhibitor geometry within the binding pocket, as suggested in the binding pose illustrated in Figure 3B . By contrast, no change in inhibitor sensitivity is measured against the mutant K400R, as compared to WT. These results confirm that the charge at K400 does not contribute to inhibitor selectivity for CLC-2 over CLC-1, the latter of which bears an arginine at this position. Finally, introduction of proline at Q399, the residue present at the equivalent position in CLC-1, reduces inhibition by AK-42 ( Figure 3D) . Together, these data support our conclusion that AK-42 binds to the predicted extracellular site on CLC-2.
Validation of AK-42 in brain-slice recordings
To validate the utility of AK-42 in neurophysiological studies, we measured CLC-2 currents in CA1 pyramidal cells of acute brain slices using whole-cell patch-clamp electrophysiology. CLC-2 currents were isolated by blocking synaptic transmission and currents mediated by voltage-gated sodium channels and hyperpolarizationactivated cyclic nucleotide-gated (HCN) channels (see Methods). To evoke CLC-2 currents, cells were stepped from -4 mV, a membrane potential at which CLC-2 channels are closed, to test potentials ranging from -100 to 30 mV. During the 3-second test pulse, CLC-2 current is observed as a slow increase in inward current at the most negative potentials (Figure 4A ). Relative to other neuronal ion channels, the CLC-2 channel activates slowly (seconds) following hyperpolarization, thereby facilitating current isolation 26, 27, [46] [47] [48] . We measured CLC-2 channel activity both in terms of the final steady-state current, as well as the amount of current change over the 4-second test step (relaxation current). Our lead compound AK-42 attenuated steady-state currents and eliminated relaxation currents in recorded neurons (Figure 4A-D) but had no effect on either measurement in neurons recorded from homozygous CLC-2 knockout (Clcn2 -/-) mice, thereby demonstrating target specificity (Figure Figure 5A-B) . These initial observations, obtained at 2.5 uM AK-2, were confirmed in experiments using a lower, but still saturating, concentration of 100 nM (Extended Data Figure 5C -E).
4E-H; Extended Data
Specificity of the inhibition was further supported by experiments showing 100 nM AK-42 has no effect on firing rate, resting membrane potential, input resistance, or membrane time constant (Extended Data Figure 5F -I).
Using the same tissue preparation, the time course for inhibition by AK-42 (100 nM) was measured (Extended Data Figure 5C ). Steady-state inhibition of CLC-2 current recorded at -80 mV in hippocampal neurons was achieved within 5-10 minutes of compound application to brain slices. AK-42 had no effect on currents recorded at -20 mV, a voltage at which little to no CLC-2 current is expected. The 5-10 minute time course for onset of inhibition is slower than the rates derived from our kinetic assays in CHO cells, but such differences are expected for a compound that must penetrate tissue to reach the intended target. Following steady-state inhibition, we evaluated reversibility by washing out AK-42 (perfusion with buffer solution) over several minutes (Extended Data Figure 5C ). Substantial recovery of hyperpolarization-induced current (66%) supports our hypothesis that the AK-42 binding site is extracellular, that the compound is not significantly internalized over the course of the experiment, and that this new probe can provide a method for acute, selective, and reversible block of CLC-2 in primary neurons.
AK-42 reveals that CLC-2 activity is seizure-protective
Having established the specificity of AK-42 for CLC-2, and given the potential role of CLC-2 in regulation of excitability and epilepsy [15] [16] [17] [18] [19] [20] [21] , we examined the effect of AK-42 on neural network excitability in a brain slice model of epilepsy that contains the thalamus, a subcortical structure. CLC-2 is enriched in the dorsal and reticular thalamus 27, 49 , two thalamic nuclei implicated in producing seizures associated with generalized epilepsies [50] [51] [52] .
Rhythmic epileptiform oscillations, which can be evoked in acute brain slices containing the two thalamic nuclei, have long served as an important model to better understand mechanisms that regulate network excitability and mediate anti-epileptic drug actions [53] [54] [55] . We therefore evaluated the effects of AK-42 on bicuculline-enhanced thalamic oscillations in acute rat brain slices, a robust model of epileptic activity [56] [57] [58] . Seconds-long network oscillations were reliably evoked by electrical stimuli (Figure 5A ). Oscillations were evoked while delivering control recording solution (ACSF with 0.001% DMSO) to slices for 20 minutes (baseline), followed by solutions containing either 100 nM AK-42 (in 0.001% DMSO) or a vehicle control (0.001% DMSO, Figure 5B , C); the experimenter was blinded to the condition. Application of the DMSO vehicle did not change the duration of evoked oscillations (Figure 5D , P = 0.34, n = 7). In contrast, AK-42 application reduced the oscillation duration by an average 0.81 s (17%) (Figure 5D , P = 0.0015, n = 12). These data show that CLC-2 inhibition suppresses epileptiform activity in vitro and suggest that CLC-2 inhibitors could be a target for anti-epileptic drug therapies.
Discussion
AK-42 represents the first molecular tool for precisely disentangling the complex effects of CLC-2 in the CNS.
The high potency and specificity of AK-42 for its target stands in contrast to all other known Clchannel smallmolecule modulators and enables acute channel inhibition, thus avoiding the interpretive challenges of genetic knockout or silencing methods. AK-42 was systematically advanced from an initial hit compound, MCFA. With an IC50 of 17 ± 1 nM, AK-42 is ~10,000 times more potent against human CLC-2 versus the next closest homolog, CLC-1. In addition to extraordinary selectivity within the CLC family, AK-42 is highly specific for CLC-2 as compared to other CNS channels, receptors, and transporters. Moreover, AK-42 acutely and specifically inhibits CLC-2-mediated current in WT hippocampal CA1 neurons recorded in brain slices, and it is reversible on the timescale of a typical brain-slice experiment. The discovery of AK-42 represents a breakthrough in CLC channel pharmacology and will enable systematic investigations of CLC-2 function.
The molecular physiology of CLC-2 remains poorly understood. Data from mouse genetic knockout studies suggest a critical role for CLC-2 in ion homeostasis and electrical excitability in the CNS, but discrete mechanisms that underlie CLC-2 activity have been difficult to elucidate in the absence of specific and potent chemical modulators of CLC-2. Two lines of experiments suggest a role for the CLC-2 channel in maintaining strong inhibitory responses at GABAergic synapses 48, 59 . Activation of the GABAA receptor opens a chloride-conductive pore within the receptor that permits the rapid influx of negatively charged Clions into cells, causing a voltage hyperpolarization that represents the primary mode of synaptic inhibition in the CNS. To ensure Clinflux, low intracellular concentrations of the ion must be maintained; the accumulation of intracellular Clfollowing rapid and successive activation of GABAA receptors can lead to cellular depolarization, a result of Clefflux [59] [60] [61] [62] . The properties of CLC-2-chiefly, Clextrusion following hyperpolarization-are thus hypothesized to provide an important means for maintaining low intracellular Clconcentration following synaptic inhibition 26, 48, 59 .
Alternatively, it has been argued that CLC-2 regulates neuronal excitability, not by maintaining low intracellular Clconcentrations through Clefflux, but rather by mediating Clinflux under physiological conditions 63 .
Both of the above proposals lead to the same hypothesis: genetic loss-of-function should result in excessive neural circuit activity and contribute to the generation of seizures. Consistent with this hypothesis, an early study reported human CLC-2 mutations as contributing to several major genetic generalized epilepsy (GGE) subtypes 14 .
This original study was retracted, however, and since this time, the role of CLC-2 in regulating seizures has been controversial 16, 17, [20] [21] [22] . Given that connections between CLC-2 mutations and epilepsies are rare in the GGE population 15, 18, 19 , it is likely that such mutations are susceptibility factors, a conclusion that generally underscores the emerging hypothesis that the common, genetically-acquired epilepsy subtypes are complex, polygenic disorders that do not arise from single mutations [64] [65] [66] [67] .
In our experiments using a well-established thalamic model of epilepsy [56] [57] [58] , we inhibited CLC-2 pharmacologically and acutely, eliminating complications in experimental interpretation that may occur as a result of developmental changes in modified genetic backgrounds. Our finding that inhibition of CLC-2 causes a downregulation of network activity is the opposite of expected based on a causal link between CLC-2 loss-offunction and epilepsy; rather, our data implicate CLC-2 as a putative target for anti-epileptics. Despite the unexpected nature of this finding, there are many potential mechanisms that might result in the anti-epileptic effects of CLC-2 inhibition, including intrinsic, e.g., alteration in neuronal excitability 63 , extrinsic (non-neuronal, e.g., astrocytic 68 ), or synaptic 48 , among others. Our discovery of AK-42, a potent and specific CLC-2 inhibitor, will enable future studies to determine the mechanism by which CLC-2 regulates excitability.
Supplementary Information
All results from the ENZO library screen are available in Supplemental Table 1 .
All specificity data from PDSP are available in Supplemental Table 2 Prior to initial screening, we validated our assay by using Cd 2+ and NPPB as positive controls for CLC-2 inhibition. Eight dose-response curves were generated in each experiment on two different days (n = 3-4 per concentration). All Z' values (a standard metric for evaluating assay quality) exceeded 0.5, indicating acceptable assay variability 69 . The Z' factor was calculated as:
where MeanVC and SDVC are the mean and standard deviation values for a vehicle control, and MeanPC and SDPC are the mean and standard deviation values for a positive control (300 µM NPPB or 1 mM Cd 2+ ). Initial screening for hit compounds was performed using the ENZO Life Sciences SCREEN-WELL ® FDA-approved drug library, v. 2.0 (Product # BML-2843-0100). All compounds in this library are reported in Supplemental Table 1 . Vehicle controls of 0.3 or 1.0% DMSO (without compound) in recording solution were applied in replicate as additional controls in each experiment.
Cell line generation
All CLC-2 recordings using the IWB platform were performed using a stably expressing Chinese hamster ovary (CHO) cell line. CHO cells were transfected with human CLC-2 cDNAs (CLCN2, GenBank Acc # NM_004366.3). Stable transfectants were selected by expression with the antibiotic-resistance gene (Geneticin/G418) incorporated into the expression plasmid (pcDNA3.1(+)). Selection pressure was maintained by including selection antibiotics in the culture medium. Cells were cultured in Ham's F-12 media (Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (HyCloneTM Fetal Bovine Serum, U.S.), 100 U/mL penicillin G sodium, 100 µg/mL streptomycin sulfate, and 500 µg/mL G418. Before testing, cells in culture dishes were washed twice with Hank's Balanced Salt Solution (HBSS, Life Technologies, Grand Island, NY), treated with Accutase™ (Innovative Cell Technologies, San Diego, CA) solution for 20 min at room temperature, and re-suspended in HBSS (4-6 × 10 6 cells in 10 mL). Immediately before use, the cells were washed twice in HBSS to remove the Accutase™ and re-suspended in 5 mL of HBSS. CLC-1 recordings were performed using a stably expressing CHO cell that was generated according to the same methods described for CLC-2.
IWB voltage protocol and data analysis
From a holding potential of -30 mV, CLC-2 currents were elicited by applying 2-second test pulses from -120 to +20 mV in 20-mV increments. Following each test pulse, a 500-ms tail pulse to 0 mV was applied. We required initial currents at the 0-mV tail pulse to be ≥ 0.2 nA to be included in analysis. All IC50 data reported in the manuscript are given according to measurements at the peak inward current at -120 mV, the point where the For the kinetics experiments (Extended Data Figure 4) , current was elicited with a 2000-ms voltage step to potential -120 mV followed by 500-ms voltage step to potential 0 mV; the holding potential was -30 mV. The test pulses were repeated with frequency 0.1 Hz. Six stimulations were applied before application of test articles (1-min baseline), and thirty stimulations were performed after application of test articles (5 min). Current amplitudes were measured as the peak inward current at test potential -120 mV and the maximal outward current at test potential 0 mV.
The vehicle control data (0.3% DMSO; n = 32) were averaged for each time point. All data were normalized to the time-matching averaged vehicle control. Then data were normalized to the baseline current recorded before application of test articles.
Cell culture & recording protocols (manual patch-clamp)
CHO K1 cells (ATCC ® CCL-61TM) were cultured at 37 °C in F12K media (ATCC, Catalog No. supplemented with 10% fetal bovine serum (GIBCO) and 1% penicillin/streptomycin (GIBCO). At 70-90% confluency, cells were transfected with full-length rat CLC-2 cDNA (449 ng), using Lipofectamine ® LTX, opti-MEM ® , and PLUS™ reagent (Invitrogen). The rat CLC-2 gene was contained in a custom plasmid vector called pFROG (ampicillin resistance), provided by Prof. Michael Pusch (Istituto di Biofisica, CNR, Genova, Italy). Cotransfection with GFP (177 ng, 2.5:1 CLC-2/GFP) was used to estimate transfection efficiency. Cells were transfected 18 hours prior to recording. Borosilicate glass micropipettes (Sutter Instruments, Novato, CA) were pulled and fire-polished to a tip diameter with a resistance of 1.5-3.0 MΩ. For whole-cell patch clamp recordings, the internal solution was composed of 148 mM CsCl, 2 mM CaCl2, 10 mM HEPES, and 100 mM D-mannitol (adjusted to pH 7.4 with 2 M aqueous CsOH). The external solution was composed of 146 mM CsCl, 5 mM EGTA, 10 mM HEPES, 5 mM NaF, and 60 mM D-mannitol (adjusted to pH 7.4 with 2 M aqueous CsOH). If necessary, the osmolarity was adjusted with D-mannitol such that it was slightly higher outside than inside in order to prevent cell swelling, which can make it difficult to establish a high-resistance seal. CLC-2 currents were measured in whole-cell patch-clamp mode, using an Axopatch-200B amplifier (Axon Instruments, Union City, CA), an InstruTECH ITC-16 interface (HEKA Instruments, Holliston, MA), and a Mac mini computer (Apple, Cupertino, CA). Igor Pro (WaveMetrics, Portland, OR) software was used for stimulation and data collection.
The data were sampled at 5 kHz and filtered at 1 kHz. From a holding potential of 0 mV, currents were elicited with 250-ms voltage steps of -100 to +20 mV in 10-mV increments, followed by a 100-ms tail pulse to +80 mV ( Figure 3C) . All experiments were carried out at room temperature (22-25 °C) . For recording, currents were measured before application of inhibitor ("initial"), after application of inhibitor ("inhibited"), and after washout of inhibitor ("washout"). For fitting dose-response curves (Extended Data Figure 3 ), we excluded experiments in which there was poor reversibility of inhibition. Poor reversibility was defined as when reversal current differed by >20% from initial current and/or inhibition calculated using washout current differed by >10% from inhibition Analysis of variance (ANOVA) was used for statistical analysis.
Mutagenesis strategy
CLC-2 mutants were generated by site-directed mutagenesis using a QuickChange XL Site-Directed Mutagenesis Kit (Agilent Technologies, Cedar Creek, TX). The following table lists primers used to generate expression vectors in this study.
Vector
Primer Sequence pFROG-CLC-2 K400R 
CLC-2 KO mice
Heterozygous CLC-2 KO mice (Clcn2 +/-) 13 were bred and litters genotyped to identify littermate Clcn2 -/and Clcn2 +/+ mice, which were paired in each experiment. On any experimental day, brain slices from a pair of young mice (P30-P45) were prepared, and then slices separated by group with the identity blinded to the investigator.
Electrophysiological recordings in acute hippocampal slices
250 µM thick coronal slices were prepared from 30-35 day old WT C57/B6J or KO (Clcn2 -/-) mice as described previously 58 and filtered at 100-3000 Hz. Custom Matlab (Natick, MA) scripts were used to detect and analyze multiunit activity. After bandpass-filtering the signal at 100-1000 Hz, spikes were detected by checking whether each point with maximum slope, occurring more than 25 ms after stimulation start (to account for the stimulus artifact), crosses a sweep-dependent slope threshold, using a slice-dependent signal-to-noise ratio of 2-3.5. Detected spikes were then grouped into 10-ms bins, from which bursts were detected by setting a minimum burst length of 20 ms and a minimum spike rate within a burst of 100 Hz. The evoked oscillation from each sweep was then defined by the maximum contiguous stretch of bursts starting from stimulation start, with inter-burst intervals no greater than 2000 ms.
Computational Docking
Initial docking studies involved preparation of the receptor and ligand using the dock prep tool in the UCSF Chimera package 71 . The receptor surface and ligand were parameterized using the AMBER parm99 force field 72 . et al. 44 , as well as CLC-2 homology models generated from the 5TQQ and 5TR1 cryo-EM structures of bovine CLC-K 45 . Alignment of the CLC-2 sequence with these structures for generation of the homology models was accomplished with the UCSF Chimera sequence alignment tool 71 . The CLC-2 sequence was then mapped onto the template structure, using the Modeller package 76 . Unresolved regions of the template structure were also refined using Modeller. Docking to the CLC-1 cryo-EM structure (6COY) 77 was performed using a grid centered on the equivalent lysine residue for this homolog (K231). Docking grids were generated using the default Maestro settings for receptor rigidity (Van der Waals radius scaling factor of 1.0 with a partial charge cutoff of 0.25).
Prepared ligands were docked to these grids using the default settings for Schrödinger Glide 78 
Chemical synthesis: General
Reagents were obtained commercially unless otherwise noted. Meclofenamate sodium, N-phenylanthranilic acid, and lubiprostone were purchased commercially from Sigma-Aldrich. Diclofenac sodium, indomethacin, and niflumic acid were purchased from Santa Cruz Biotechnology. Salsalate was purchased from ACROS Organics.
Aceclofenac was purchased from AK Scientific. Organic solutions were concentrated under reduced pressure 
Inhibitor stock solution preparation and quantification
Meclofenamic acid (MCFA) derivatives were quantified by 1 H NMR spectroscopy using distilled N,Ndimethylformamide (DMF) as an internal standard. Use of DMF as the internal standard allows for recovery of pure material following lyophilization. Each MCFA derivative was weighed into an Eppendorf tube, using a calibrated analytical balance (Mettler Toledo, Model XS105), and dissolved into DMSO-d6 to a final concentration of 30-100 mM. To ensure complete dissolution, the sealed Eppendorf tube was inverted at least 5 times and then sonicated for ~60 seconds. Using a calibrated analytical balance, DMF (22 mg) was weighed into a scintillation vial, 3.0 mL DMSO-d6 (stored in a desiccator jar and preferably newly opened to minimize water contamination in the solvent) was added to the vial via a p1000 micropipette, and the solution thoroughly mixed by inverting the capped vial at least 10 times (note: to prevent cross-contamination between samples and for convenience, disposable micropipette tips may be used without affecting the accuracy of the measurements). To ensure robustness of the quantification protocol, the 100 mM DMF stock solution was independently quantified in triplicate against stock solutions with known concentrations of fumaronitrile dissolved in DMSO-d6.
Fumaronitrile produces a sharp singlet that integrates to 2H at 7.03 ppm in DMSO-d6 (DMSO solvent residual peak referenced to 2.50 ppm) and may be integrated against either of the DMF methyl signals that appear at 2.73 ppm (3H) and 2.89 (3H) ppm. The average of these three NMR measurements was used for calculation of the final DMF internal standard concentration. All measurements were performed at room temperature. Stock solutions were stored frozen and left at ambient temperature for several hours to thaw and vortexed prior to quantification. A relaxation delay time (d1) of 20 s and an acquisition time (at) of 10 s were used during spectral acquisition. The number of scans was typically set to 32 unless a particular compound concentration was low (< 10 mM) such that more scans were required to improve signal/noise. The concentration of each MCFA derivative was determined by comparison with signal integrations for the MCFA derivative and the DMF internal standard. Figure 3C and references 39, 79, 80 or in a different automated patch-clamp platform (PatchXpress, unpublished data), is likely due to the differences in the intracellular solution, which in this case includes a mixture of Cland F -. Right: Summary data for inhibition of CLC-2 by Cd 2+ (± SEM, n = 4-32; IC50 = 3.1 ± 0.3 µM). Inhibition was calculated using the maximum current at -120 mV in the presence or absence of Cd 2+ . Assay-validation studies showed a Z-factor of 0.83 and 0. 
EXDENDED DATA FIGURE 2
Extended Data Figure 2 . SAR studies around the AK-24 scaffold. The bar graphs shows the inverse IC50, estimated from inhibition at four concentrations (n = 3-4 each concentration), as in Figure 1 . Substitutions around the -OBn ring are destabilizing. Combining the substitutions of AK-24 and AK-33 has a synergistic effect on inhibitor potency (AK-42). Data are tabulated in Extended Data Table 2 .
EXTENDED DATA TABLE 2
Top Table: Approximate IC50 values of fenamate derivatives against CLC-2, determined from 4 concentrations with the IWB platform. Compounds are listed according to position of modification as shown in Figure 1B and groups are colored accordingly. Bottom IC50 values were determined from data in panel (B); these differ slightly from IC50 values obtained in the initial screen ( Fig. 1) , which used only four concentrations of each compound. (B) Inhibition at -120 mV was determined using the IWB, n = 3-4 for each concentration ± SEM. Fits to the Hill equation yield IC50 values of 7 ± 1 µM, 1.2 ± 0.2 µM, 3 ± 1 µM, and 0.017 ± 0.001 µM for MCFA, AK-24, AK-33, and AK-42 respectively (Extended Data Table 3 ). (C) Inhibition curves for AK-42 against CLC-1 and CLC-2 determined using the IWB, illustrating that AK-42 is ~10,000 times more potent against CLC-2 compared to the most closely related CLC homolog (individual data points are shown in Extended Data Table 4 ). Table 5 . These data support that AK-42 binds in the pocket predicted by our docking studies. 
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